NEW ORLEANS — A dose of intravitreal bevacizumab as low as 0.031 mg was successful in treating acute, severe retinopathy of prematurity in a small cohort of infant patients, a speaker said here.
“Doses as low as 5% of what was used and considered the standard dose in the BEAT-ROP study were successful in nine out of nine infants, although some infants required additional treatment,” David K. Wallace, MD, MPH, said at the American Academy of Ophthalmology meeting.
Wallace and colleagues conducted a dose de-escalation study of 10 to 14 (Read more...)
Uncategorized